Congenital Myasthenic Syndrome (CMS)

What is Congenital Myasthenic Syndrome (CMS)?

Congenital Myasthenic Syndrome is a group of rare inherited disorders that affect how your nerves and muscles communicate. When you decide to move a muscle, your nerves release a chemical messenger called acetylcholine that tells the muscle to contract. In people with CMS, this communication system does not work properly due to genetic mutations present from birth.

This condition causes muscle weakness and fatigue that gets worse with physical activity and improves with rest. The severity can range from mild to severe and depends on which gene is affected. Unlike myasthenia gravis, which is an autoimmune condition, CMS is caused by inherited genetic changes passed down from parents to children.

Different types of CMS affect different parts of the nerve-muscle connection. Some affect the nerve ending, others affect the space between the nerve and muscle, and still others affect the muscle side of the connection. Each type may respond differently to treatment, which is why accurate diagnosis through genetic testing is important.

MuSK and LRP4 Antibodies Panel

Pinpoint muscle weakness causes accurately
Reveal autoimmune issues affecting your health
Clarify unexplained fatigue and muscle pain

^$7,400

Symptoms

Muscle weakness that worsens with activity and improves with rest
Drooping eyelids that may get worse as the day progresses
Double vision or difficulty moving the eyes
Weak cry or difficulty sucking in infants
Delayed motor development in children
Difficulty swallowing or choking on food
Weak facial muscles or lack of facial expression
Breathing difficulties, especially during illness or exertion
Muscle fatigue during repetitive movements like chewing
Episodes of sudden severe weakness triggered by infection or stress

Most people with CMS show symptoms in infancy or early childhood. However, some milder forms may not become noticeable until adolescence or adulthood. Symptoms can vary widely even among family members with the same genetic mutation.

Causes and risk factors

Congenital Myasthenic Syndrome is caused by mutations in genes that control how nerves and muscles communicate. These genetic changes are inherited from one or both parents, depending on the specific type of CMS. More than 30 different genes have been linked to various forms of CMS. Each gene plays a role in building or maintaining the neuromuscular junction, which is where nerve cells connect to muscle cells.

The most common genes affected include CHRNE, RAPSN, COLQ, DOK7, and CHAT. Some forms follow an autosomal recessive pattern, meaning a child must inherit a mutated gene from both parents to develop the condition. Other forms follow an autosomal dominant pattern, where inheriting one mutated gene is enough to cause symptoms. Parents who carry one copy of a recessive gene mutation typically show no symptoms themselves but can pass the mutation to their children.

How it's diagnosed

Diagnosing Congenital Myasthenic Syndrome requires specialized testing beyond standard blood work. Doctors typically start with a detailed medical history and physical examination, looking for patterns of muscle weakness that improve with rest. Electromyography, or EMG, tests the electrical activity of muscles and can show characteristic patterns seen in CMS. Repetitive nerve stimulation tests may reveal a decrease in muscle response that helps distinguish CMS from other conditions.

Genetic testing is essential for confirming the diagnosis and identifying the specific gene mutation. This helps guide treatment decisions since different types of CMS respond differently to medications. In some cases, muscle biopsy may be performed to examine the neuromuscular junction under a microscope. Blood tests for antibodies like MuSK Antibodies may be ordered to rule out autoimmune myasthenia gravis, which can look similar but requires different treatment. Talk to your doctor about specialized testing if you or your child shows signs of muscle weakness. Our team can help connect you with appropriate diagnostic resources.

Treatment options

Acetylcholinesterase inhibitors like pyridostigmine for some types of CMS
3,4-diaminopyridine to improve nerve signal transmission
Ephedrine or albuterol for certain genetic subtypes
Avoiding medications that can worsen muscle weakness, including some antibiotics and anesthetics
Physical therapy to maintain muscle strength and prevent contractures
Occupational therapy to help with daily activities and adaptive equipment
Respiratory support including ventilation during illness or severe episodes
Genetic counseling for families to understand inheritance patterns
Regular monitoring by a neuromuscular specialist
Avoiding overexertion and planning rest periods during activities

Frequently asked questions

Congenital Myasthenic Syndrome is caused by inherited genetic mutations present from birth that affect the nerve-muscle connection. Myasthenia gravis is an autoimmune condition where the body produces antibodies that attack the same connection. CMS typically appears in infancy or childhood, while myasthenia gravis usually develops in adulthood. The two conditions require different treatments, so accurate diagnosis through genetic and antibody testing is important.

Standard blood tests cannot directly detect CMS since it is caused by genetic mutations rather than blood abnormalities. However, blood tests for antibodies like MuSK Antibodies may be ordered to rule out autoimmune myasthenia gravis, which can look similar. Genetic testing, which uses a blood or saliva sample, is the primary way to confirm CMS and identify the specific gene mutation involved.

The severity of CMS varies widely depending on the specific genetic mutation and how well symptoms respond to treatment. Many people with CMS live full lives with proper management and monitoring. Some forms can cause life-threatening breathing difficulties, especially during infancy or during infections. Early diagnosis and appropriate treatment are key to preventing serious complications and maintaining quality of life.

Most people with Congenital Myasthenic Syndrome show symptoms in infancy or early childhood, often within the first two years of life. Infants may have a weak cry, difficulty feeding, or delayed motor milestones like sitting or walking. However, milder forms may not become noticeable until adolescence or even adulthood. The age of onset and severity depend on which gene is affected and the specific mutation.

Most forms of CMS follow an autosomal recessive inheritance pattern, meaning a child must inherit a mutated gene from both parents to develop the condition. Parents who each carry one copy of the mutation typically show no symptoms themselves. Some rarer forms follow an autosomal dominant pattern, where inheriting one mutated gene from either parent is enough to cause symptoms. Genetic counseling can help families understand their specific inheritance pattern and risks for future children.

People with Congenital Myasthenic Syndrome should avoid certain medications that can worsen muscle weakness. These include some antibiotics like aminoglycosides and fluoroquinolones, magnesium supplements, beta-blockers, and certain anesthetics. Some types of CMS can actually worsen with acetylcholinesterase inhibitors that help other types. Always inform doctors, dentists, and pharmacists about your CMS diagnosis before taking any new medication.

Gentle, regular exercise can help maintain muscle strength and function in people with Congenital Myasthenic Syndrome. However, overexertion can trigger severe weakness and fatigue. The key is finding a balance between staying active and not pushing muscles beyond their limits. Physical therapy can help develop an appropriate exercise program that includes frequent rest breaks and avoids activities that cause excessive fatigue.

No, different genetic types of Congenital Myasthenic Syndrome respond differently to medications. Some types improve with acetylcholinesterase inhibitors like pyridostigmine, while others may actually worsen with these drugs. Some respond well to 3,4-diaminopyridine or ephedrine. This is why genetic testing to identify the specific mutation is so important, as it guides doctors to choose the most effective treatment for each person.

Pregnancy can affect CMS symptoms differently in different people. Some women experience worsening weakness during pregnancy due to increased physical demands on the body. Others may notice no change or even temporary improvement. Close monitoring by both a neuromuscular specialist and obstetrician is important during pregnancy. Some medications used to treat CMS may need to be adjusted or changed to ensure safety for both mother and baby.

Genetic testing for family members depends on the inheritance pattern and family planning goals. If CMS follows a recessive pattern, siblings have a 25 percent chance of being affected and a 50 percent chance of being carriers. Parents may want to know their carrier status when planning future children. Genetic counseling can help families understand their risks and make informed decisions about testing.